Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Gerlinger

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Science (New York, N.Y.)|December 21, 2019
Targeted drugs ramp up cancer mutabilityMarco Gerlinger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2018
Metastasis Seeding Cells: Lone Invaders or Mass Migrators?Marco Gerlinger
European Urology|February 7, 2015
Translating Seminoma Genomic Landscapes into Clinical PracticeMarco Gerlinger
Cancer Cell|January 12, 2021
Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not EnoughMarco Gerlinger
Nature Biomedical Engineering|December 22, 2023
Assessing the toxicity of bispecific antibodiesMarta Buzzetti, Marco Gerlinger
Nature Ecology & Evolution|October 20, 2017
Cancer (r)evolutionKatharina von Loga, Marco Gerlinger
The New England Journal of Medicine|September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Marco Gerlinger, Larry Norton, Charles Swanton
The Journal of Biological Chemistry|November 2, 2005
Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loopJoerg Kumbrink, Marco Gerlinger, Judith P Johnson
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapyMarco Gerlinger, Peter Wilson, Thomas Powles, et al.
Current Opinion in Genetics & Development|January 3, 2015
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scaleLouise J Barber, Matthew N Davies, Marco Gerlinger
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Science (New York, N.Y.)|December 21, 2019
Targeted drugs ramp up cancer mutabilityMarco Gerlinger
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2018
Metastasis Seeding Cells: Lone Invaders or Mass Migrators?Marco Gerlinger
European Urology|February 7, 2015
Translating Seminoma Genomic Landscapes into Clinical PracticeMarco Gerlinger
Cancer Cell|January 12, 2021
Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not EnoughMarco Gerlinger
Nature Biomedical Engineering|December 22, 2023
Assessing the toxicity of bispecific antibodiesMarta Buzzetti, Marco Gerlinger
Nature Ecology & Evolution|October 20, 2017
Cancer (r)evolutionKatharina von Loga, Marco Gerlinger
The New England Journal of Medicine|September 20, 2013
Acquired resistance to crizotinib from a mutation in CD74-ROS1Marco Gerlinger, Larry Norton, Charles Swanton
The Journal of Biological Chemistry|November 2, 2005
Egr-1 induces the expression of its corepressor nab2 by activation of the nab2 promoter thereby establishing a negative feedback loopJoerg Kumbrink, Marco Gerlinger, Judith P Johnson
European Journal of Cancer (Oxford, England : 1990)|August 17, 2010
Elevated LDH predicts poor outcome of recurrent germ cell tumours treated with dose dense chemotherapyMarco Gerlinger, Peter Wilson, Thomas Powles, et al.
Current Opinion in Genetics & Development|January 3, 2015
Dissecting cancer evolution at the macro-heterogeneity and micro-heterogeneity scaleLouise J Barber, Matthew N Davies, Marco Gerlinger
Pageof 7